PTH-157 The Introduction of Biosimilar Infliximab (CT-P13) through A Managed Switching Programme Generates Significant Cost Savings with High Levels of Patient Satisfaction
PTH-157 The Introduction of Biosimilar Infliximab (CT-P13) through A Managed Switching Programme Generates Significant Cost Savings with High Levels of Patient Satisfaction